← Back to headlines
Jazz Pharmaceuticals Forecasts 2026 Revenue, Awaits Zanidatamab PDUFA
Jazz Pharmaceuticals projects its 2026 revenue to be between $4.60 billion and $4.75 billion, as the company anticipates an August 25 PDUFA date for its drug zanidatamab.
4 Aug, 01:10 — 4 Aug, 01:10
Sources
Showing 1 of 1 sources
